A citation-based method for searching scientific literature

G MacGrogan, L Mauriac, M Durand, F Bonichon, M Trojani, I de Mascarel, J M Coindre. Br J Cancer 1996
Times Cited: 170







List of co-cited articles
638 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
I F Faneyte, J G Schrama, J L Peterse, P L Remijnse, S Rodenhuis, M J van de Vijver. Br J Cancer 2003
220
36

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H M Kuerer, L A Newman, T L Smith, F C Ames, K K Hunt, K Dhingra, R L Theriault, G Singh, S M Binkley, N Sneige,[...]. J Clin Oncol 1999
31

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998
30

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, R G Margolese, A B Cruz, E R Fisher, D L Wickerham, N Wolmark,[...]. J Clin Oncol 1997
26

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer.
S Rozan, A Vincent-Salomon, B Zafrani, P Validire, P De Cremoux, A Bernoux, M Nieruchalski, A Fourquet, K Clough, V Dieras,[...]. Int J Cancer 1998
151
23

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
J Chang, T J Powles, D C Allred, S E Ashley, G M Clark, A Makris, L Assersohn, R K Gregory, C K Osborne, M Dowsett. J Clin Oncol 1999
190
23

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
A Makris, T J Powles, M Dowsett, C K Osborne, P A Trott, I N Fernando, S E Ashley, M G Ormerod, J C Titley, R K Gregory,[...]. Clin Cancer Res 1997
127
21

Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.
M Colleoni, I Minchella, G Mazzarol, F Nolè, G Peruzzotti, A Rocca, G Viale, L Orlando, G Ferretti, G Curigliano,[...]. Ann Oncol 2000
80
23


Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
R J Burcombe, A Makris, P I Richman, F M Daley, S Noble, M Pittam, D Wright, S A Allen, J Dove, G D Wilson. Br J Cancer 2005
129
17

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
G Bonadonna, P Valagussa, C Brambilla, L Ferrari, A Moliterni, M Terenziani, M Zambetti. J Clin Oncol 1998
440
16

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Ann Brown, Roy Smith, Eleftherios P Mamounas, Bernard Fisher, Richard Margolese, Heather Theoret, Atilla Soran, D Lawrence Wickerham,[...]. J Clin Oncol 2003
794
16


Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Edwin R Fisher, Jiping Wang, John Bryant, Bernard Fisher, Eletherios Mamounas, Norman Wolmark. Cancer 2002
281
15

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
15

Prediction of response to primary chemotherapy for operable breast cancer.
M Colleoni, E Orvieto, F Nolé, L Orlando, I Minchella, G Viale, G Peruzzotti, C Robertson, C Noberasco, V Galimberti,[...]. Eur J Cancer 1999
82
17

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Jenny C Chang, Eric C Wooten, Anna Tsimelzon, Susan G Hilsenbeck, M Carolina Gutierrez, Richard Elledge, Syed Mohsin, C Kent Osborne, Gary C Chamness, D Craig Allred,[...]. Lancet 2003
635
14


Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
S Geisler, P E Lønning, T Aas, H Johnsen, O Fluge, D F Haugen, J R Lillehaug, L A Akslen, A L Børresen-Dale. Cancer Res 2001
265
13

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Valentina Guarneri, Kristine Broglio, Shu-Wan Kau, Massimo Cristofanilli, Aman U Buzdar, Vicente Valero, Thomas Buchholz, Funda Meric, Lavinia Middleton, Gabriel N Hortobagyi,[...]. J Clin Oncol 2006
436
13

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
D M Sataloff, B A Mason, A J Prestipino, U L Seinige, C P Lieber, Z Baloch. J Am Coll Surg 1995
338
12

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
G Bonadonna, U Veronesi, C Brambilla, L Ferrari, A Luini, M Greco, C Bartoli, G Coopmans de Yoldi, R Zucali, F Rilke. J Natl Cancer Inst 1990
495
12

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Marco Colleoni, Giuseppe Viale, David Zahrieh, Giancarlo Pruneri, Oreste Gentilini, Paolo Veronesi, Richard D Gelber, Giuseppe Curigliano, Rosalba Torrisi, Alberto Luini,[...]. Clin Cancer Res 2004
262
12

Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
J Chang, M Ormerod, T J Powles, D C Allred, S E Ashley, M Dowsett. Cancer 2000
141
12

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Aman U Buzdar, Nuhad K Ibrahim, Deborah Francis, Daniel J Booser, Eva S Thomas, Richard L Theriault, Lajos Pusztai, Marjorie C Green, Banu K Arun, Sharon H Giordano,[...]. J Clin Oncol 2005
824
12

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.
A Makris, T J Powles, D C Allred, S E Ashley, P A Trott, M G Ormerod, J C Titley, M Dowsett. Breast Cancer Res Treat 1999
59
18

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J A van der Hage, C J van de Velde, J P Julien, M Tubiana-Hulin, C Vandervelden, L Duchateau. J Clin Oncol 2001
749
11

Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer.
M G Daidone, S Veneroni, E Benini, G Tomasic, D Coradini, M Mastore, C Brambilla, L Ferrari, R Silvestrini. Int J Cancer 1999
46
23

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Ian C Smith, Steven D Heys, Andrew W Hutcheon, Iain D Miller, Simon Payne, Fiona J Gilbert, Antoinne K Ah-See, Oleg Eremin, Leslie G Walker, Tarun K Sarkar,[...]. J Clin Oncol 2002
552
11

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
D Kandioler-Eckersberger, C Ludwig, M Rudas, S Kappel, E Janschek, C Wenzel, H Schlagbauer-Wadl, M Mittlböck, M Gnant, G Steger,[...]. Clin Cancer Res 2000
214
11

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.
E Niskanen, C Blomqvist, K Franssila, P Hietanen, V M Wasenius. Br J Cancer 1997
75
13

Clinical and pathological response to primary chemotherapy in operable breast cancer.
P Chollet, S Charrier, E Brain, H Curé, I van Praagh, V Feillel, M de Latour, J Dauplat, J L Misset, J P Ferrière. Eur J Cancer 1997
89
11

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
A D Thor, D A Berry, D R Budman, H B Muss, T Kute, I C Henderson, M Barcos, C Cirrincione, S Edgerton, C Allred,[...]. J Natl Cancer Inst 1998
494
10


Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, Marc J van de Vijver, Yudong D He, Augustinus A M Hart, Mao Mao, Hans L Peterse, Karin van der Kooy, Matthew J Marton, Anke T Witteveen,[...]. Nature 2002
10

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
A Bottini, A Berruti, A Bersiga, M P Brizzi, A Brunelli, G Gorzegno, B DiMarco, S Aguggini, G Bolsi, F Cirillo,[...]. Clin Cancer Res 2000
109
10

A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Vered Stearns, Baljit Singh, Theodore Tsangaris, Jeanette G Crawford, Antonella Novielli, Mathew J Ellis, Claudine Isaacs, Marie Pennanen, Cecilia Tibery, Ahmad Farhad,[...]. Clin Cancer Res 2003
90
11

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer.
A Bottini, A Berruti, A Bersiga, M P Brizzi, P Bruzzi, S Aguggini, A Brunelli, G Bolsi, G Allevi, D Generali,[...]. Br J Cancer 2001
67
14

ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy.
A Vincent-Salomon, M Carton, P Freneaux, T Palangie, P Beuzeboc, E Mouret, P de Crémoux, O Coué, B Zafrani, A Nicolas,[...]. Eur J Cancer 2000
44
20

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
P C Clahsen, C J van de Velde, C Duval, C Pallud, A M Mandard, A Delobelle-Deroide, L van den Broek, T M Sahmoud, M J van de Vijver. J Clin Oncol 1998
143
9

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
T J Powles, T F Hickish, A Makris, S E Ashley, M E O'Brien, V A Tidy, S Casey, A G Nash, N Sacks, D Cosgrove. J Clin Oncol 1995
281
9

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
S Paik, J Bryant, C Park, B Fisher, E Tan-Chiu, D Hyams, E R Fisher, M E Lippman, D L Wickerham, N Wolmark. J Natl Cancer Inst 1998
547
9

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.
S M Scholl, A Fourquet, B Asselain, J Y Pierga, J R Vilcoq, J C Durand, T Dorval, T Palangié, M Jouve, P Beuzeboc. Eur J Cancer 1994
333
9


Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.
Frédérique Penault-Llorca, Anne Cayre, Florence Bouchet Mishellany, Sophie Amat, Viviane Feillel, Guillaume Le Bouedec, Jean-Pierre Ferrière, Monique De Latour, Philippe Chollet. Int J Oncol 2003
57
15

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
M Ayers, W F Symmans, J Stec, A I Damokosh, E Clark, K Hess, M Lecocke, J Metivier, D Booser, N Ibrahim,[...]. J Clin Oncol 2004
404
9

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
M-C Mathieu, R Rouzier, A Llombart-Cussac, L Sideris, S Koscielny, J P Travagli, G Contesso, S Delaloge, M Spielmann. Eur J Cancer 2004
120
9


Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
Gunter von Minckwitz, Hans-Peter Sinn, Günter Raab, Sibylle Loibl, Jens-Uwe Blohmer, Holger Eidtmann, Jörn Hilfrich, Elisabeth Merkle, Christian Jackisch, Serban D Costa,[...]. Breast Cancer Res 2008
89
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.